KBC Group
IMNM icon

KBC Group’s Immunome IMNM Stock Holding History

KBC Group’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58K Hold
2,739
– – ﹤0.01% 1662
2026
Q1 		$60K Buy
+2,739
New +$61K ﹤0.01% 1585
2024
Q2 		– Sell
-1,011
Closed -$25K – 1882
2024
Q1 		$25K Buy
+1,011
New +$20.5K ﹤0.01% 1807

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

KBC Group's IMNM Position: Q2 2026 in Review

KBC Group held its Immunome (IMNM) position steady in Q2 2026 at 2,739 shares worth $58K. The position accounts for ﹤0.01% of the portfolio, ranked #1662.

KBC Group first reported a position in IMNM in Q1 2024 and has held it in 3 quarters since. The position peaked at $60K in Q1 2026. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • KBC Group held 2,739 shares of Immunome worth $58K as of Q2 2026.
  • KBC Group left its Immunome share count unchanged in Q2 2026.
  • Immunome made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1662 holding.
  • KBC Group first reported a position in Immunome in Q1 2024 and has held it in 3 quarters since.
  • KBC Group's Immunome position peaked at $60K in Q1 2026.
  • 203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.